GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect & identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, & state-of-the-art computer science & data science to enhance the scientific understanding of cancer biology, & to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, & the United Kingdom. GRAIL is a wholly-owned subsidiary of Illumina (NASDAQ:ILMN). For more information, please visit www.grail.com.
GRAIL, is developing differentiated platforms for the early detection of cancer. These platforms combine approaches to ultradeep sequencing of circulating, cell-free nucleic acids with innovative clinical programs of the scale & quality required to generate strong scientific & clinical evidence of their utility. GRAIL's software & computational biology efforts are commensurate to the size & complexity of the resulting data sets. We are seeking passionate & talented individuals to join us in realizing our mission, which has the potential to dramatically reduce the global burden of cancer.
In this role, you will build & manage a team at the forefront of NGS assay R&D to create the assay platforms to meet GRAIL's research & product goals. Working cross-functionally with computational, software, clinical & operational groups you will execute critical R&D projects. You will be an author & champion of GRAIL's R&D processes & advocate of GRAIL's scientific culture of rigor.
|
